Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
11 NC counties are under alert, including Johnston County.
Closings
1 closing/delay reported.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,137.10
-13.09 (-1.14%)
Streaming Delayed Price
Updated: 2:36 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
33
34
35
36
37
38
39
40
Next >
7 European Stocks to Buy to Diversify Your Portfolio
November 04, 2021
While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks.
Via
InvestorPlace
Regeneron Pharmaceuticals Earnings Perspective: Return On Invested Capital
November 04, 2021
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q3 earnings of $1.85 billion, an increase from Q2 of 44.81%. Sales dropped to $3.45 billion, a 32.81...
Via
Benzinga
Why Regeneron Shares Are Rising Today
November 04, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced better-than-expected third-quarter financial results. Regeneron reported...
Via
Benzinga
How Regeneron's Covid Drug Lent Itself To A Big Third-Quarter Beat
November 04, 2021
Regeneron reported $804 million in sales of its Covid antibody cocktail, REGEN-COV.
Via
Investor's Business Daily
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Will Regeneron Be Worth More Than Amazon by 2030?
October 28, 2021
Regeneron's market value has climbed more than 1,000% in a decade.
Via
The Motley Fool
Exposures
COVID-19
Where Regeneron Pharmaceuticals Stands With Analysts
October 26, 2021
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
October 22, 2021
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach.
Via
Investor's Business Daily
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
October 18, 2021
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a...
Via
Benzinga
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
October 18, 2021
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....
Via
Benzinga
Exposures
Product Safety
3 No-Brainer Biotech Stocks to Buy Right Now
October 16, 2021
Regeneron Pharmaceuticals, Vertex Pharmaceuticals, and Viatris should have plenty of room to run.
Via
The Motley Fool
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
October 15, 2021
Companies working on sorely needed Covid treatments are innovating to keep up.
Via
Investor's Business Daily
2 Cheap Growth Stocks That Could Be Even Better Buys in November
October 15, 2021
Both of these companies are reporting earnings within the next month, and there could be a dip in price that follows.
Via
The Motley Fool
Why Regeneron Shares Are Rising Today
October 14, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced the FDA accepted for priority review a Biologics License Application for...
Via
Benzinga
Exposures
Product Safety
Expert Ratings For Regeneron Pharmaceuticals
October 12, 2021
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has obser...
Via
Benzinga
AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial
October 11, 2021
AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...
Via
Benzinga
Exposures
COVID-19
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure...
Via
FinancialNewsMedia
Exposures
COVID-19
Regeneron Could Have a Big Catalyst Coming in 2022
October 09, 2021
Cancer drug Libtayo could receive FDA approval for its fourth indication in January.
Via
The Motley Fool
Exposures
Product Safety
Cramer Likes DraftKings, Skyworks, And These Automakers
October 07, 2021
On CNBC's "Mad Money Lightning Rou...
Via
Benzinga
Tesla and Merck Give Investors Some Hope
October 04, 2021
Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
October 01, 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new...
Via
Benzinga
Why Moderna, Novavax And Other COVID-19 Vaccine Stocks Are Plummeting
October 01, 2021
The COVID-19 pandemic proved to be a boon for many biopharma companies that benefited from their foray into the development of vaccines and/or treatments against the novel...
Via
Benzinga
Exposures
COVID-19
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization
October 01, 2021
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
< Previous
1
2
...
33
34
35
36
37
38
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.